prednicarbate

(redirected from Dermatop)
Also found in: Wikipedia.

corticosteroid

 [kor″tĭ-ko-ster´oid]
any of the hormones produced by the adrenal cortex; also, their synthetic equivalents. Called also adrenocortical hormone and adrenocorticoid. All the hormones are steroids having similar chemical structures, but quite different physiologic effects. Generally they are divided into glucocorticoids (cortisol, cortisone, and corticosterone), mineralocorticoids (aldosterone and desoxycorticosterone, and also corticosterone) and androgens.

Patients who must take exogenous adrenal corticosteroids to supplement a deficit in endogenous cortisol or as a treatment for metastatic breast cancer should be thoroughly instructed in self-medication. Their needs are somewhat similar to those of the insulin-dependent diabetic patient. They should know the prescribed dosage and basic therapeutic action of the oral corticosteroid preparation they are taking and should be aware of the importance of taking the medication at the same time every day. The medication should never be discontinued abruptly for any reason. It is advisable that the patient carry an extra prescription when traveling, in case the supply is used up before returning home. These patients also need to wear some form of medical identification so that all health care professionals with whom they come in contact will know that they are receiving hormones of this kind. This includes dentists, oral surgeons, emergency department personnel, and others who might not be familiar with the patient's medical history.

prednicarbate

/pred·ni·car·bate/ (pred″nĭ-kahr´bāt) a synthetic corticosteroid used topically for the relief of inflammation and pruritus in certain dermatoses.

prednicarbate

[pred′n-kahr′bāt]
a synthetic corticosteroid used topically for the relief of inflammation and pruritus in certain dermatoses.

prednicarbate (pred´nəkär´bāt),

n brand name: Dermatop Emollient Cream;
drug class: topical corticosteroid, group III potency;
action: possesses antipruritic, antiinflammatory actions;
uses: relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
References in periodicals archive ?
The bill will also prevent competition for other critical drugs, including Cardiogen 82 (radiologic imaging), Daypro (arthritis), Dermatop (skin ailments), Eulexin (prostate cancer), Nimotop (stroke), Penetrex (urinary tract infection) and Relafen (arthritis).
Cleared for marketing by the Therapeutic Products Programme (TPP), DERMATOP is available by prescription now in pharmacies throughout Canada, as an ointment or an emollient cream.
Other drugs covered by the bill that would continue to be sold free of price-dropping competition are: Cardiogen-82 (radiologic imaging), Daypro (arthritis), Dermatop (skin ailments), Eulexin (prostate cancer), Nimotop (stroke), Penetrex (urinary tract infections) and Relafen (arthritis).
Seniors will be especially harmed by the "Claritin Patent Extension Act" because 35 percent of older Americans pay out-of-pocket for medicine and use most of the drugs protected under the bill, including: Cardiogen-82 (radiologic imaging), Claritin (allergies), Daypro (arthritis), Dermatop (skin ailments), Eulexin (prostate cancer), Nimotop (stroke), Penetrex (urinary tract infections) and Relafen (arthritis).
Seniors will be hardest-hit because 35 percent of older Americans pay out-of-pocket for medicine and use most of the drugs protected under the bill, including: Cardiogen-82 (radiologic imaging), Daypro (arthritis), Dermatop (skin ailments), Eulexin (prostate cancer), Nimotop (stroke), Penetrex (urinary tract infections), and Relafen (arthritis).
1172 passes because 35 percent of older Americans pay out- of-pocket for medicine and use most of the drugs protected under the bill, including: Cardiogen-82 (radiologic imaging), Daypro (arthritis), Dermatop (skin ailments), Eulexin (prostate cancer), Nimotop (stroke), Penetrex (urinary tract infections) and Relafen (arthritis).
Seniors will be hardest hit because 35 percent of older Americans pay out-of-pocket for medicine and use most of the drugs protected under the bill, including: Cardiogen-82 (radiologic imaging), Daypro (arthritis), Dermatop (skin ailments), Eulexin (prostate cancer), Nimotop (stroke), Penetrex (urinary tract infections), and Relafen (arthritis).
DERMATOP is the only mid-potency topical steroid approved for use in pediatric patients one (1) year of age and older.
Drugs protected under the bill include Claritin and Eulexin (prostate cancer/Schering-Plough), Daypro (arthritis/Monsanto), Dermatop (skin ailments/Hoechst Marion Roussel), Penetrex (urinary tract infections/Rhone-Poulenc-Rorer), Cardiogen-82 (radiologic imaging/Bristol-Myers Squibb), Nimotop (stroke/Bayer A.
The drugs include Claritin and Eulexin (prostate cancer/Schering-Plough), Dermatop (skin ailments/Hoechst Marion Roussel), Penetrex (urinary tract infections/Rhone- Poulenc-Rorer), Cardiogen-82 (radiologic imaging/Bristol-Myers Squibb), Nimotop (stroke/Bayer A.
DermAtop gives physicians a midpotency alternative that is gentle enough even for patients with chronic dermatoses and elderly patients.
In addition, Hoechst-Roussel will seek permission to market Dermatop (prednicarbate) emollient cream, a novel, non-halogenated medium potency corticosteroid.